Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial (vol 116, pg 191, 2016)

Stefano Barco, Mareike Lankeit, Harald Binder, Sebastian Schellong, Michael Christ, Jan Beyer-Westendorf, Daniel Duerschmied, Rupert Bauersachs, Klaus Empen, Matthias Held, Martin Schwaiblmair, Cândida Fonseca, David Jimenez, Cecilia Becattini, Kurt Quitzau, Christine Espinola-Klein, Philipp Wild, Stavros Konstantinides

Research output: Contribution to journalBook/Film/Article review

Original languageEnglish
Pages (from-to)775
Number of pages1
JournalTHROMBOSIS AND HAEMOSTASIS
Volume116
Issue number4
DOIs
Publication statusPublished - Oct 2016

Cite this

Barco, S., Lankeit, M., Binder, H., Schellong, S., Christ, M., Beyer-Westendorf, J., Duerschmied, D., Bauersachs, R., Empen, K., Held, M., Schwaiblmair, M., Fonseca, C., Jimenez, D., Becattini, C., Quitzau, K., Espinola-Klein, C., Wild, P., & Konstantinides, S. (2016). Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial (vol 116, pg 191, 2016). THROMBOSIS AND HAEMOSTASIS, 116(4), 775. https://doi.org/10.1160/TH16100001